ALX Oncology | ApexOnco - Clinical Trials news and analysis

x

“The insights provided by the analysts are great”

Andrea Gnirke-Maier

Director New Product Planning

Morphosys

Click here for more information

Trial results

9 February 2024

CD47’s long goodbye

Despite magrolimab’s latest flop, efforts to target CD47 continue.

Trial results

3 October 2023

What’s that, a win for CD47?

ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.

Deals

26 September 2023

Against the odds biopharma throws all it can at CD47

Subscribe to ALX Oncology